1,209 Shares in Thermo Fisher Scientific Inc. (NYSE:TMO) Purchased by Harfst & Associates Inc.

Key Points

• Harfst & Associates Inc. acquired 1,209 shares of Thermo Fisher Scientific Inc. valued at approximately $602,000, marking the company's entry as a new stakeholder during the first quarter.
• Thermo Fisher achieved earnings of $5.36 per share this quarter, surpassing analysts' expectations, with a revenue of $10.86 billion, reflecting a 2.9% increase year-over-year.
• The company declared a quarterly dividend of $0.43 to be paid on October 15, with a 0.4% dividend yield and a payout ratio of 9.95%.

Harfst & Associates Inc. purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,209 shares of the medical research company's stock, valued at approximately $602,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of TMO. Bernard Wealth Management Corp. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth about $25,000. Ameriflex Group Inc. bought a new stake in Thermo Fisher Scientific during the 4th quarter worth about $30,000. IMA Advisory Services Inc. acquired a new position in Thermo Fisher Scientific during the 1st quarter valued at about $35,000. Navigoe LLC acquired a new position in Thermo Fisher Scientific during the 4th quarter valued at about $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new position in Thermo Fisher Scientific during the 1st quarter valued at about $37,000. Institutional investors own 89.23% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Wells Fargo & Company dropped their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a report on Thursday, July 24th. Hsbc Global Res downgraded shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. HSBC restated a "hold" rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Barclays raised their target price on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a report on Thursday, July 24th. Finally, Argus decreased their price target on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Seven research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $593.00.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total value of $4,518,200.00. Following the completion of the sale, the chief executive officer owned 115,174 shares in the company, valued at $52,037,916.68. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,400 shares of company stock valued at $8,345,792. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO traded up $4.92 during midday trading on Friday, reaching $489.96. 2,462,453 shares of the stock were exchanged, compared to its average volume of 3,069,315. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The company has a market cap of $185.01 billion, a P/E ratio of 28.34, a PEG ratio of 2.61 and a beta of 0.74. The stock's 50 day simple moving average is $434.83 and its 200 day simple moving average is $460.05.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. Thermo Fisher Scientific's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.37 earnings per share. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's payout ratio is 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.